[Retracted] Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

Table 2

The best response to pyrrotinib targeted therapy for all HER2-positive breast cancer patients.

Efficacy	Second-line ()	Third-line ()	Total
CR	1 (4.55)	1 (7.69)	2 (5.71)
PR	12 (54.55)	3 (23.08)	15 (42.86)
SD	8 (36.36)	7 (53.85)	15 (42.86)
PD	1 (4.55)	2 (15.38)	3 (8.57)
ORR	13 (59.09)	4 (30.77)	17 (48.57)
DCR	21 (95.45)	11 (84.62)	33 (94.29)
Survival rate [ (%)]	17 (77.27)	9 (69.23)	26 (74.29)